Skip to content
Search

Latest Stories

Menopause treatment: 3 HRT medicines to be removed from HRT PPC list

Menopause treatment: 3 HRT medicines to be removed from HRT PPC list
Longjam Dineshwori
By Longjam DineshworiJul 29, 2024
Longjam Dineshwori

A passionate journalist with a keen interest in health and pharma, I strive to tell stories that inform, inspire, and drive meaningful change.

See Full Bio

Pharmacy staff are advised to check the NHSBSA website for the updated list of HRT medicine covered by the HRT PPC 

Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme.

These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets.

Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no longer available as a licensed HRT medicine.

The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC.

Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC.

The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.

The HRT medicines list has been updated following consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), NHSBSA and the NHS England Menopause Clinical Reference Group.

The list is regularly revised to include new HRT medicines licensed for menopause treatment in the UK or to remove those that are discontinued.

For any HRT medicines meeting the criteria that are missing from the list, pharmacy teams can contact dhsc.publicenquiries@dhsc.gov.uk.

In February 2023, the Department of Health and Social Care (DHSC) introduced the HRT prescription prepayment certificate (HRT PPC) to provide patients in England access to cheaper Hormone Replacement Therapy (HRT) for menopause.

Starting 1 April 2023, patients who do not qualify for exemption from NHS prescription charges could purchase an annual HRT PPC for the cost of two single prescription charges.

HRT PPCs only cover HRT medicines that are also licensed for the treatment of menopause in the UK.

“community pharmacy england”hrt medicinenhs business services authoritymenopause

Related News

Pharmacists working together, symbolizing unity for the Royal College of Pharmacy
Breaking news

Breaking News: RPS members vote in favour of Royal College

Economic analysis of pharmacy finances will be published ‘imminently’ - Stephen Kinnock
News

NPA collective action “premature, unnecessary and detrimental to patients” - Stephen Kinnock

NPA members are expected reduce opening hours and services from next week
News

NPA will become more “militant” as wait for pharmacy contract goes on

Community pharmacy services
Guest Blog

Expanding community pharmacy services - a blueprint for the future

More For You

Community pharmacy needs investment and support to deliver neighbourhood health, says CCA chief

Community pharmacies see patients more than anyone else in the primary care system.

Getty Images

Community pharmacy key to neighbourhood health, but investment needed, says CCA chief

Community pharmacies can play a vital role in delivering a ‘neighbourhood health service’, provided they receive the necessary investment and support, according to Malcolm Harrison, chief executive of the Company Chemists’ Association (CCA).

Harrison's comments come in response to a new report from think tank Reform, titled Designing a Neighbourhood Health Service, which outlines key principles for achieving the government's vision of a more community-focused healthcare system.

Keep ReadingShow less
Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc